Chemogenomics in drug discovery.
暂无分享,去创建一个
[1] Hugo Kubinyi,et al. Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective , 2004 .
[2] R. Willette,et al. Identification and in vivo efficacy of small-molecule antagonists of integrin αvβ3 (the vitronectin receptor) , 2000 .
[3] G. Müller,et al. Medicinal chemistry of target family-directed masterkeys. , 2003, Drug discovery today.
[4] Gerhard Müller,et al. Target Family‐Directed Masterkeys in Chemogenomics , 2005 .
[5] A. Hopkins,et al. Navigating chemical space for biology and medicine , 2004, Nature.
[6] Peter G. Schultz,et al. Synthetic small molecules that control stem cell fate , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[7] B. Shoichet,et al. A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.
[8] R. Hilgenfeld,et al. Utility of homology models in the drug discovery process , 2004, Drug Discovery Today.
[9] C. Wermuth. Selective optimization of side activities: another way for drug discovery. , 2004, Journal of medicinal chemistry.
[10] F. Bymaster,et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α 1-adrenergic receptors in vitro , 1999, Schizophrenia Research.
[11] C. Wermuth,et al. 5-HT3 antagonists derived from aminopyridazine-type muscarinic M1 agonists. , 1998, Journal of medicinal chemistry.
[12] R G Smith,et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. , 1998, Science.
[13] Peteris Prusis,et al. Proteochemometrics: A Tool for Modeling the Molecular Interaction Space , 2005 .
[14] H. Kubinyi,et al. 3D QSAR in drug design. , 2002 .
[15] K. Bleicher,et al. Chemogenomics: bridging a drug discovery gap. , 2002, Current medicinal chemistry.
[16] Gerd Folkers,et al. Ligand-protein interactions and molecular similarity , 1998 .
[17] S. Schreiber. PERSPECTIVE: THE SMALL-MOLECULE APPROACH TO BIOLOGYChemical genetics and diversity-oriented organic synthesis make possible the systematic exploration of biology , 2003 .
[18] B. Stockwell. Exploring biology with small organic molecules , 2004, Nature.
[19] A. Hillisch,et al. Protein structure-based design, synthesis strategy and in vitro pharmacological characterization of estrogen receptor alpha and beta selective compounds. , 2004, Ernst Schering Research Foundation workshop.
[20] Koh Jt,et al. A subtype-selective thyromimetic designed to bind a mutant thyroid hormone receptor implicated in resistance to thyroid hormone. , 2001 .
[21] Hugo Kubinyi,et al. Similarity and Dissimilarity: A Medicinal Chemist’s View , 2002 .
[22] T. Scanlan,et al. Selective thyromimetics: tissue-selective thyroid hormone analogs. , 2001, Current opinion in drug discovery & development.
[23] R. Fletterick,et al. Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. , 2002, Endocrinology.
[24] Brian K Shoichet,et al. Kinase inhibitors: not just for kinases anymore. , 2003, Journal of medicinal chemistry.
[25] C. E. Peishoff,et al. Discovery of Potent Nonpeptide Vitronectin Receptor (αVβ3) Antagonists , 1997 .
[26] María L. López-Rodríguez,et al. Comparative receptor mapping of serotoninergic 5-HT3 and 5-HT4 binding sites* , 1997, J. Comput. Aided Mol. Des..
[27] S. Schreiber,et al. Target-oriented and diversity-oriented organic synthesis in drug discovery. , 2000, Science.
[28] B. Shoichet,et al. Identification and prediction of promiscuous aggregating inhibitors among known drugs. , 2003, Journal of medicinal chemistry.
[29] B. Shoichet,et al. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.
[30] Peter G. Schultz,et al. A chemical switch for inhibitor-sensitive alleles of any protein kinase , 2000, Nature.
[31] Edgar Jacoby,et al. Chemogenomics knowledge-based strategies in drug discovery. , 2003, Drug news & perspectives.
[32] Alex Matter,et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.
[33] Philip Seeman,et al. Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine , 1996, Neuropsychopharmacology.
[34] W. Michne,et al. The Value of Chemical Genetics in Drug Discovery , 2005 .
[35] Stuart L. Schreiber,et al. Stereoselective Synthesis of over Two Million Compounds Having Structural Features Both Reminiscent of Natural Products and Compatible with Miniaturized Cell-Based Assays , 1998 .
[36] C. Wermuth. The Sosa approach: An alternative to high-throughput screening , 2001 .
[37] T. Petcher,et al. An opioid benzodiazepine , 1982, Nature.
[38] W. Sneader. Drug prototypes and their exploitation , 1996 .
[39] C. E. Peishoff,et al. Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists. , 1996, Journal of medicinal chemistry.
[40] H. Kubinyi. Drug Discovery from Side Effects , 2005 .
[41] Gisbert Schneider,et al. Navigation in Chemical Space: Ligand‐Based Design of Focused Compound Libraries , 2005 .
[42] S. Haggarty,et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. , 1999, Science.
[43] Hirosato Kondo,et al. Design and synthesis of dual inhibitors for matrix metalloproteinase and cathepsin. , 2002, Bioorganic & medicinal chemistry letters.
[44] Alexander Hillisch,et al. Dissecting Physiological Roles of Estrogen Receptor α and β with Potent Selective Ligands from Structure-Based Design , 2004 .
[45] M. Murcko,et al. Chemogenomic approaches to drug discovery. , 2001, Current opinion in chemical biology.
[46] J. Robl,et al. Dual metalloprotease inhibitors.v. Utilization of bicyclic azepinonethiazolidines and azepinonetetrahydrothiazines in constrained peptidomimetics of mercaptoacyl dipeptides , 1995 .
[47] Arthur A. Patchett,et al. Chapter 26. Privileged structures — An update , 2000 .
[48] A. Maureen Rouhi. MOVING BEYOND NATURAL PRODUCTS , 2003 .
[49] B. E. Evans,et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of medicinal chemistry.
[50] T. Insel,et al. NIH Molecular Libraries Initiative , 2004, Science.